AVEO Pharmaceuticals, Inc. (AVEO) Expected to Post Quarterly Sales of $790,000.00
Wall Street analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will post sales of $790,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $1.08 million. AVEO Pharmaceuticals posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 83.7%. The firm is scheduled to issue its next earnings results on Tuesday, August 6th.
On average, analysts expect that AVEO Pharmaceuticals will report full year sales of $10.62 million for the current year, with estimates ranging from $2.00 million to $24.30 million. For the next year, analysts forecast that the company will report sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $2.48 million. AVEO Pharmaceuticals had a net margin of 70.30% and a negative return on equity of 20.94%.
Shares of NASDAQ AVEO traded down $0.08 during mid-day trading on Monday, hitting $0.82. The company’s stock had a trading volume of 4,467,232 shares, compared to its average volume of 6,300,979. The firm has a market capitalization of $134.99 million, a PE ratio of -4.30 and a beta of 1.21. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.
In other news, major shareholder Equity Opportunities Fu Growth purchased 4,347,827 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 4.40% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. NEA Management Company LLC raised its position in shares of AVEO Pharmaceuticals by 11.8% in the 4th quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock valued at $33,434,000 after acquiring an additional 2,198,000 shares during the period. BlackRock Inc. raised its position in shares of AVEO Pharmaceuticals by 3.3% in the 4th quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after acquiring an additional 236,822 shares during the period. Vanguard Group Inc raised its holdings in AVEO Pharmaceuticals by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock worth $16,770,000 after buying an additional 73,519 shares during the period. Vanguard Group Inc. raised its holdings in AVEO Pharmaceuticals by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock worth $16,770,000 after buying an additional 73,519 shares during the period. Finally, Geode Capital Management LLC raised its holdings in AVEO Pharmaceuticals by 36.3% during the 4th quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock worth $2,231,000 after buying an additional 371,327 shares during the period. Institutional investors and hedge funds own 30.92% of the company’s stock.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
See Also: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.